

Harry Moultrie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2261218/publications.pdf>

Version: 2024-02-01

62
papers

4,616
citations

182225

30
h-index

139680

61
g-index

66
all docs

66
docs citations

66
times ranked

5844
citing authors

#	ARTICLE	IF	CITATIONS
1	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. <i>Lancet, The</i> , 2022, 399, 437-446.	6.3	818
2	Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. <i>Science</i> , 2022, 376, eabn4947.	6.0	651
3	Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 494-496.	13.9	570
4	Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children. <i>New England Journal of Medicine</i> , 2012, 366, 2380-2389.	13.9	172
5	The Contribution of Maternal HIV Seroconversion During Late Pregnancy and Breastfeeding to Mother-to-Child Transmission of HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 417-425.	0.9	129
6	Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 428-437.	0.9	119
7	Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africaâ€”The leDEA Southern Africa Collaboration. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 270-278.	0.9	112
8	The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 603-622.	5.2	99
9	Challenges to Pediatric HIV Care and Treatment in South Africa. <i>Journal of Infectious Diseases</i> , 2007, 196, S474-S481.	1.9	94
10	Outcomes of the South African National Antiretroviral Treatment Programme for children: the leDEA Southern Africa collaboration. <i>South African Medical Journal</i> , 2009, 99, 730-7.	0.2	93
11	Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 524-532.	0.9	88
12	Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe. <i>Clinical Infectious Diseases</i> , 2012, 55, 1707-1718.	2.9	68
13	Effectiveness of Ad26.COVS.2 and BNT162b2 Vaccines against Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 2243-2245.	13.9	65
14	Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 496-506.	4.6	53
15	Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. <i>PLoS ONE</i> , 2017, 12, e0186557.	1.1	52
16	Effectiveness of the Ad26.COVS.2 vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. <i>Lancet, The</i> , 2022, 399, 1141-1153.	6.3	51
17	Antiretroviral Therapy Responses Among Children Attending a Large Public Clinic in Soweto, South Africa. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 974-979.	1.1	50
18	Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. <i>Aids</i> , 2013, 27, 1933-1940.	1.0	48

#	ARTICLE	IF	CITATIONS
19	Variability of Growth in Children Starting Antiretroviral Treatment in Southern Africa. <i>Pediatrics</i> , 2012, 130, e966-e977.	1.0	46
20	The Effect of Early Initiation of Antiretroviral Treatment in Infants on Pediatric AIDS Mortality in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 474-480.	1.1	46
21	Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the leDEA Southern Africa collaboration. <i>South African Medical Journal</i> , 2009, 99, 653-60.	0.2	44
22	Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 543-549.	1.3	42
23	Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. <i>Aids</i> , 2010, 24, 1341-1349.	1.0	41
24	A survey of paediatric HIV programmatic and clinical management practices in Asia and sub-Saharan Africa—the International epidemiologic Databases to Evaluate AIDS (leDEA). <i>Journal of the International AIDS Society</i> , 2013, 16, 17998.	1.2	37
25	Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. <i>Global Health Action</i> , 2013, 6, 19248.	0.7	36
26	Temporal Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in Southern Africa: The leDEA-SA Collaboration. <i>PLoS ONE</i> , 2013, 8, e81037.	1.1	36
27	Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment. <i>PLoS ONE</i> , 2011, 6, e17273.	1.1	35
28	Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. <i>Journal of the International AIDS Society</i> , 2012, 15, 5-5.	1.2	34
29	Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. <i>Aids</i> , 2010, 24, 139-146.	1.0	33
30	Alcohol use and sexual risk behaviour among men and women in inner-city Johannesburg, South Africa. <i>BMC Public Health</i> , 2017, 17, 548.	1.2	33
31	When to Start Antiretroviral Therapy in Children Aged 2–5 Years: A Collaborative Causal Modelling Analysis of Cohort Studies from Southern Africa. <i>PLoS Medicine</i> , 2013, 10, e1001555.	3.9	32
32	Virologic Response in Children Treated With Abacavir-compared With Stavudine-based Antiretroviral Treatment. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 617-622.	1.1	29
33	Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab040.	0.4	27
34	Tuberculosis Immune Reconstitution Inflammatory Syndrome in Children Initiating Antiretroviral Therapy for HIV Infection. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 499-503.	1.1	25
35	Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 273-277.	1.1	24
36	Prognosis of Children With HIV-1 Infection Starting Antiretroviral Therapy in Southern Africa. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 608-616.	1.1	24

#	ARTICLE	IF	CITATIONS
37	A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. <i>Journal of the International AIDS Society</i> , 2011, 14, 7-7.	1.2	23
38	Cost and outcomes of paediatric antiretroviral treatment in South Africa. <i>Aids</i> , 2013, 27, 243-250.	1.0	23
39	Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. <i>Aids</i> , 2013, 27, 781-785.	1.0	22
40	Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy – The leDEA Southern Africa Collaboration. <i>Tropical Medicine and International Health</i> , 2011, 16, 1367-1371.	1.0	21
41	Immune Recovery After Starting ART in HIV-Infected Patients Presenting and Not Presenting With Tuberculosis in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 142-145.	0.9	21
42	Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. <i>Tropical Medicine and International Health</i> , 2013, 18, 194-198.	1.0	20
43	Virologic Failure Among Children Taking Lopinavir/Ritonavir-containing First-line Antiretroviral Therapy in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 175-179.	1.1	20
44	Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa. <i>Frontiers in Microbiology</i> , 2016, 7, 1947.	1.5	20
45	Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children. <i>Pediatric Pulmonology</i> , 2016, 51, 157-164.	1.0	17
46	Predictors of Virologic and Clinical Response to Nevirapine versus Lopinavir/Ritonavir-based Antiretroviral Therapy in Young Children With and Without Prior Nevirapine Exposure for the Prevention of Mother-to-child HIV Transmission. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 846-854.	1.1	16
47	Viral load versus CD4+ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa. <i>Aids</i> , 2014, 28, 2451-2460.	1.0	12
48	Focus on adolescents with HIV and AIDS. <i>South African Medical Journal</i> , 2014, 104, 897.	0.2	11
49	Effect of Baseline Immune Suppression on Growth Recovery in HIV Positive South African Children Receiving Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 235-242.	0.9	10
50	Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. <i>PLoS Medicine</i> , 2022, 19, e1004024.	3.9	10
51	The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure. <i>Tropical Medicine and International Health</i> , 2012, 17, 1386-1390.	1.0	9
52	Evaluation of the intensified tuberculosis case finding guidelines for children living with HIV. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 1322-1328.	0.6	9
53	The Effect of Tuberculosis Treatment on Virologic and Immunologic Response to Combination Antiretroviral Therapy Among South African Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 136-144.	0.9	5
54	Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 676-681.	0.6	5

#	ARTICLE	IF	CITATIONS
55	A position statement and practical guide to the use of particulate filtering facepiece respirators (N95,) Tj ETQq1 1 0.784314 rgBT /Over Mycobacterium tuberculosis and SARS-CoV-2. African Journal of Thoracic and Critical Care Medicine, 2021, 26, .	0.3	5
56	A geospatial analysis of two-hour surgical access to district hospitals in South Africa. BMC Health Services Research, 2020, 20, 744.	0.9	4
57	Growth in Virologically Suppressed HIV-Positive Children on Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2015, 34, e254-e259.	1.1	3
58	CHAPAS-3 fills the gap. Lancet Infectious Diseases, The, 2016, 16, 133-134.	4.6	2
59	Outcomes in treatment with darunavir/ritonavir in ART-experienced paediatric patients. South African Medical Journal, 2015, 105, 330.	0.2	2
60	Protective Effect of HIV-Positive Primary Caregivers on Mortality in Children Receiving Antiretroviral Therapy?. Journal of Infectious Diseases, 2008, 198, 939-940.	1.9	1
61	Novel biomarkers for paediatric tuberculosis. Lancet Infectious Diseases, The, 2014, 14, 900-901.	4.6	1
62	Advancing TB research using digitized programmatic data. International Journal of Tuberculosis and Lung Disease, 2021, 25, 890-895.	0.6	1